Meeting
2022 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ).
Authors
Maria A Velez
David Geffen School of Medicine at UCLA, Los Angeles, CA
Maria A Velez , Amy Lauren Cummings , Matthew C Mulroy , Edward B. Garon , Dennis J. Slamon , Jonathan W. Goldman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8582)
DOI
10.1200/JCO.2022.40.16_suppl.8582
Abstract #
8582
Poster Bd #
208
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).
First Author: Matthew C Mulroy
Poster
2022 ASCO Annual Meeting
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
First Author: Jonathan W. Goldman
Poster
2020 ASCO Virtual Scientific Program
A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).
First Author: Amy Lauren Cummings
Poster
2016 ASCO Annual Meeting
VERTU: Veliparib, radiotherapy (RT) and temozolomide (TMZ) trial in unmethylated MGMT glioblastoma (GBM).
First Author: Mustafa Khasraw